Search
forLearn
5 / 801 resultslearn Phospholipids
learn oligopeptide-71
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Biotinyl-GHK
Research
5 / 899 results
research Effect of sinapic acid on hair growth promoting in human hair follicle dermal papilla cells via Akt activation
Sinapic acid may help hair growth by activating a specific cell pathway.
research Extracellular Signal-Regulated Kinase Mediates Ebastine-Induced Human Follicle Dermal Papilla Cell Proliferation
Ebastine may promote hair regrowth by increasing cell growth through the ERK pathway.
research PBX homeobox 1 enhances hair follicle mesenchymal stem cell proliferation and reprogramming through activation of the AKT/glycogen synthase kinase signaling pathway and suppression of apoptosis
PBX1 helps hair stem cells grow and change by turning on certain cell signals and preventing cell death, which may be useful for hair regrowth treatments.
research Skin Adipocyte Stem Cell Self-Renewal Is Regulated by a PDGFA/AKT-Signaling Axis
PDGFA/AKT signaling is important for the growth and maintenance of certain skin fat cells.
research Exercise activates the PI3K-AKT signal pathway by decreasing the expression of 5α-reductase type 1 in PCOS rats
Exercise improves insulin sensitivity and hormone regulation in PCOS rats.
Community Join
5 / 1000+ resultscommunity Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.